Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Oncology Patients Receiving Chemotherapy 1 Neoplasms 1 Lung Neoplasms 1 Hypersensitivity 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Breast Neoplasms 1

Interventions

Dexamethasone 3 iniparib 2 Ultrasonography 2 Poly(ADP-ribose) Polymerase Inhibitors 2 Calcium Dobesilate 2 Blood Specimen Collection 2 tislelizumab 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 asparaginase erwinia chrysanthemi recombinant 1 amminedichloro(2-methylpyridine)platinum(II) 1 ZD4054 1 Vincristine 1 Sodium Chloride 1 Rituximab 1 Paclitaxel 1 Narrow Band Imaging 1 Methotrexate 1 Mammography 1 Lenalidomide 1 Immune Checkpoint Inhibitors 1 High-Energy Shock Waves 1 Doxorubicin 1 Dexrazoxane 1 Cytarabine 1 Cetirizine 1 Carboplatin 1 BNT162 Vaccine 1 Asparaginase 1 2019-nCoV Vaccine mRNA-1273 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Hypersensitivity × Cetirizine × Clear all

NCT06039137 2024-09-25

H1-Switch

Erasmus Medical Center

Hypersensitivity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡